SCHEMBL2844914

SCHEMBL2844914

Cn1cc(-c2nccc(Oc3ccc4nc(NCC5CCCCC5)sc4c3)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 3/20 0.41
TTK P33981 1/20 0.40
PCSK9 Q8NBP7 1/20 0.40
CSF1R P07333 10/20 0.40
RAF1 P04049 1/20 0.39
BRAF P15056 1/20 0.39
ITK Q08881 1/20 0.39
PDGFRB P09619 3/20 0.39
PDGFRA P16234 3/20 0.39
FLT3 P36888 3/20 0.39
PI4KA P42356 2/20 0.38
PIK3CG P48736 2/20 0.38
PI4KB Q9UBF8 2/20 0.38
PIK3CA P42336 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
RAB9A P51151 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
PIK3CD O00329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676454 0.87 CSF1R (0.49) TTKPCSK9CSF1RRAF1BRAF
SCHEMBL2845075 0.85 CSF1R (0.40) IRAK1TTKPCSK9CSF1RITK
SCHEMBL2843107 0.85 CSF1R (0.39) TTKPCSK9CSF1RITKPDGFRB
SCHEMBL2843106 0.85 CSF1R (0.39) TTKPCSK9CSF1RITKPDGFRB
SCHEMBL2843796 0.83 CSF1R (0.57) IRAK1CSF1RPDGFRBPDGFRAFLT3
SCHEMBL2846605 0.81 CSF1R (0.47) CSF1RPDGFRBPDGFRAFLT3PI4KA
SCHEMBL2677134 0.77 CSF1R (0.48) CSF1RRAF1BRAFITKPDGFRB
SCHEMBL2850448 0.77 PIK3CD (0.44) CSF1RPDGFRBPDGFRAFLT3PI4KA
SCHEMBL2677450 0.75 CSF1R (0.49) CSF1RRAF1BRAFITKPDGFRB
SCHEMBL2676754 0.75 CSF1R (0.48) CSF1RRAF1BRAFPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 IRAK1 32/4885TTK 2495/4885PCSK9 4304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.